01 September 2003
Long term survival in a patient with malign pleuralmesothelioma after gemcitabine treatment
Ugur Coskun, Nazan Gunel, Yesim YildirimCase Rep Clin Pract Rev 2003; 4(2):92-93 :: ID: 429040
Abstract
Background: Malign pleural mesothelioma is a chemoresistant tumor. Despite of advancement in chemoterapeutic agent, its prognosis remains poor.Case Report: Gemcitabine can be used as first line therapy in malign mesothelioma with a responce rate of 7% to 30%. Second line agents in this tumor are ineffective. We present a malign pleural mesothelioma (MPM) case treated with gemcitabine as a second line agent. Conclusions: Long term survival is achived with gemcitabine threapy in MPM.
Keywords: Mesothelioma, Gemcitabine, Survival
In Press
21 Sep 2023 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.941337
21 Sep 2023 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.941422
21 Sep 2023 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.941599
21 Sep 2023 : Case report 
Am J Case Rep In Press; DOI: 10.12659/AJCR.941877
Most Viewed Current Articles
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
07 Dec 2021 : Case report 
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250